Zentalis Pharmaceuticals’ $200.2 Million Common Stock Offering

Latham & Watkins represented Zentalis Pharmaceuticals in the transaction. Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Warby Parker’s Direct Listing

Latham & Watkins represented Warby Parker Inc. in the transaction. Warby Parker Inc. executed its direct listing on the New York Stock Exchange under the ticker symbol...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here